Cargando…

The representation of Indigenous peoples in chronic disease clinical trials in Australia, Canada, New Zealand, and the United States

BACKGROUND: Indigenous peoples are overrepresented with chronic health conditions and experience suboptimal outcomes compared with non-Indigenous peoples. Genetic variations influence therapeutic responses, thus there are potential risks and harm when extrapolating evidence from the general populati...

Descripción completa

Detalles Bibliográficos
Autores principales: Umaefulam, Valerie, Kleissen, Tessa, Barnabe, Cheryl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847750/
https://www.ncbi.nlm.nih.gov/pubmed/34991361
http://dx.doi.org/10.1177/17407745211069153
_version_ 1784652112646373376
author Umaefulam, Valerie
Kleissen, Tessa
Barnabe, Cheryl
author_facet Umaefulam, Valerie
Kleissen, Tessa
Barnabe, Cheryl
author_sort Umaefulam, Valerie
collection PubMed
description BACKGROUND: Indigenous peoples are overrepresented with chronic health conditions and experience suboptimal outcomes compared with non-Indigenous peoples. Genetic variations influence therapeutic responses, thus there are potential risks and harm when extrapolating evidence from the general population to Indigenous peoples. Indigenous population–specific clinical studies, and inclusion of Indigenous peoples in general population clinical trials, are perceived to be rare. Our study (1) identified and characterized Indigenous population–specific chronic disease trials and (2) identified the representation of Indigenous peoples in general population chronic disease trials conducted in Australia, Canada, New Zealand, and the United States. METHODS: For Objective 1, publicly available clinical trial registries were searched from May 2010 to May 2020 using Indigenous population–specific terms and included for data extraction if in pre-specified chronic disease. For identified trials, we extracted Indigenous population group identity and characteristics, type of intervention, and funding type. For Objective 2, a random selection of 10% of registered clinical trials was performed and the proportion of Indigenous population participants enrolled extracted. RESULTS: In total, 170 Indigenous population–specific chronic disease trials were identified. The clinical trials were predominantly behavioral interventions (n = 95). Among general population studies, 830 studies were randomly selected. When race was reported in studies (n = 526), Indigenous individuals were enrolled in 172 studies and constituted 5.6% of the total population enrolled in those studies. CONCLUSION: Clinical trials addressing chronic disease conditions in Indigenous populations are limited. It is crucial to ensure adequate representation of Indigenous peoples in clinical trials to ensure trial data are applicable to their clinical care.
format Online
Article
Text
id pubmed-8847750
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-88477502022-02-17 The representation of Indigenous peoples in chronic disease clinical trials in Australia, Canada, New Zealand, and the United States Umaefulam, Valerie Kleissen, Tessa Barnabe, Cheryl Clin Trials Articles BACKGROUND: Indigenous peoples are overrepresented with chronic health conditions and experience suboptimal outcomes compared with non-Indigenous peoples. Genetic variations influence therapeutic responses, thus there are potential risks and harm when extrapolating evidence from the general population to Indigenous peoples. Indigenous population–specific clinical studies, and inclusion of Indigenous peoples in general population clinical trials, are perceived to be rare. Our study (1) identified and characterized Indigenous population–specific chronic disease trials and (2) identified the representation of Indigenous peoples in general population chronic disease trials conducted in Australia, Canada, New Zealand, and the United States. METHODS: For Objective 1, publicly available clinical trial registries were searched from May 2010 to May 2020 using Indigenous population–specific terms and included for data extraction if in pre-specified chronic disease. For identified trials, we extracted Indigenous population group identity and characteristics, type of intervention, and funding type. For Objective 2, a random selection of 10% of registered clinical trials was performed and the proportion of Indigenous population participants enrolled extracted. RESULTS: In total, 170 Indigenous population–specific chronic disease trials were identified. The clinical trials were predominantly behavioral interventions (n = 95). Among general population studies, 830 studies were randomly selected. When race was reported in studies (n = 526), Indigenous individuals were enrolled in 172 studies and constituted 5.6% of the total population enrolled in those studies. CONCLUSION: Clinical trials addressing chronic disease conditions in Indigenous populations are limited. It is crucial to ensure adequate representation of Indigenous peoples in clinical trials to ensure trial data are applicable to their clinical care. SAGE Publications 2022-01-06 2022-02 /pmc/articles/PMC8847750/ /pubmed/34991361 http://dx.doi.org/10.1177/17407745211069153 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 Lficense (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Articles
Umaefulam, Valerie
Kleissen, Tessa
Barnabe, Cheryl
The representation of Indigenous peoples in chronic disease clinical trials in Australia, Canada, New Zealand, and the United States
title The representation of Indigenous peoples in chronic disease clinical trials in Australia, Canada, New Zealand, and the United States
title_full The representation of Indigenous peoples in chronic disease clinical trials in Australia, Canada, New Zealand, and the United States
title_fullStr The representation of Indigenous peoples in chronic disease clinical trials in Australia, Canada, New Zealand, and the United States
title_full_unstemmed The representation of Indigenous peoples in chronic disease clinical trials in Australia, Canada, New Zealand, and the United States
title_short The representation of Indigenous peoples in chronic disease clinical trials in Australia, Canada, New Zealand, and the United States
title_sort representation of indigenous peoples in chronic disease clinical trials in australia, canada, new zealand, and the united states
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847750/
https://www.ncbi.nlm.nih.gov/pubmed/34991361
http://dx.doi.org/10.1177/17407745211069153
work_keys_str_mv AT umaefulamvalerie therepresentationofindigenouspeoplesinchronicdiseaseclinicaltrialsinaustraliacanadanewzealandandtheunitedstates
AT kleissentessa therepresentationofindigenouspeoplesinchronicdiseaseclinicaltrialsinaustraliacanadanewzealandandtheunitedstates
AT barnabecheryl therepresentationofindigenouspeoplesinchronicdiseaseclinicaltrialsinaustraliacanadanewzealandandtheunitedstates
AT umaefulamvalerie representationofindigenouspeoplesinchronicdiseaseclinicaltrialsinaustraliacanadanewzealandandtheunitedstates
AT kleissentessa representationofindigenouspeoplesinchronicdiseaseclinicaltrialsinaustraliacanadanewzealandandtheunitedstates
AT barnabecheryl representationofindigenouspeoplesinchronicdiseaseclinicaltrialsinaustraliacanadanewzealandandtheunitedstates